转移性乳腺癌患者BRCA1/2及其他panel基因突变与预后关联研究
该前瞻性队列研究对PRAEGNANT注册库中2595例转移性乳腺癌患者进行胚系癌症易感基因检测,发现10.4%携带12个已知乳腺癌易感基因突变,BRCA1/2突变占5.0%;BRCA1突变者脑转移比例更高(27.1% vs 12.8%),但突变状态未显著影响无进展生存或总生存。
要点
- 转移性乳腺癌患者胚系突变频率达10.4%,显著高于非转移性乳腺癌的6.6%。
- BRCA1突变者脑转移比例为27.1%,高于非突变者的12.8%。
- 胚系突变状态未显著改变转移性乳腺癌患者的无进展生存或总生存。
核心结论
- 由于BRCA1/2及其他乳腺癌易感基因胚系突变频率高,可考虑对所有转移性乳腺癌患者进行多基因panel检测。
- 突变携带者与非携带者的转移性乳腺癌预后相似,但肿瘤特征差异对治疗和靶向治疗研究有意义。
研究设计与样本
- 前瞻性队列研究,纳入PRAEGNANT注册库中2595例转移性乳腺癌患者,评估胚系癌症易感基因突变。
- 将已知乳腺癌易感基因突变频率与非转移性乳腺癌前瞻性注册库(同QIAseq方法测序)及公开参照对照进行比较。
- 分析突变状态与肿瘤特征、无进展生存和总生存的关联。
主要发现
- 271例(10.4%)患者检出12个已知乳腺癌易感基因(包括BRCA1和BRCA2)的胚系突变。
- 129例(5.0%)患者携带BRCA1或BRCA2突变。
- BRCA1突变携带者脑转移比例为27.1%,非突变携带者为12.8%。
- 转移性乳腺癌患者突变频率显著高于非转移性乳腺癌患者(10.4% vs 6.6%,P < .01)。
- 胚系突变未显著改变转移性乳腺癌患者的无进展生存或总生存。
临床怎么用
- 可考虑对所有转移性乳腺癌患者进行多基因panel检测以明确胚系突变状态。
- BRCA1突变携带者脑转移比例较高,临床需关注脑转移筛查与监测。
- 突变状态不影响预后评估,但肿瘤特征差异可用于指导治疗选择及靶向治疗研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS: Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. RESULTS: Germline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. CONCLUSION: Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.
引用
- Fasching PA, Yadav S, Hu C, et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol. 2021. PMID: 33780288. doi:10.1200/JCO.20.01200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。